Login to Your Account



Other News To Note


Tuesday, May 15, 2012
• Biovest International Inc., a subsidiary of Accentia Biopharmaceuticals Inc., both of Tampa, Fla., said it plans to file a marketing authorization application with the European Medicines Agency (EMA) for BiovaxID, its personalized cancer vaccine in follicular non-Hodgkin's lymphoma, following pre-filing meetings with the EMA.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription